Characterization of a Synthetic Peptide from Type IV Collagen That Promotes Melanoma Cell Adhesion, Spreading, and Motility

Mary K. Chelberg, James B. McCarthy, Amy P. N. Skubitz, Leo T. Furcht, and Effie C. Tsilibary
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455

Abstract. The adhesion and motility of tumor cells on basement membranes is a central consideration in tumor cell invasion and metastasis. Basement membrane type IV collagen directly promotes the adhesion and migration of various tumor cell types in vitro. Our previous studies demonstrated that tumor cells adhered and spread on surfaces coated with intact type IV collagen or either of the two major enzymatically purified domains of this protein. Only one of these major domains, the pepsin-generated major triple helical fragment, also supported tumor cell motility in vitro, implicating the involvement of the major triple helical region in type IV collagen-mediated tumor cell invasion in vivo. The present studies extend our previous observations using a synthetic peptide approach. A peptide, designated IV-H1, was derived from a continuous collagenous region of the major triple helical domain of the human al(IV) chain. This peptide, which has the sequence GVKGDKGNPGWPGAP2, directly supported the adhesion, spreading, and motility of the highly metastatic K1735 M4 murine melanoma cell line, as well as the adhesion and spreading of other cell types, in a concentration-dependent manner in vitro. Furthermore, excess soluble peptide IV-H1, or polyclonal antibodies directed against peptide IV-H1, inhibited type IV collagen-mediated melanoma cell adhesion, spreading, and motility, but had no effect on these cellular responses to type I collagen. The full complement of cell adhesion, spreading, and motility promoting activities was dependent upon the preservation of the three prolyl residues in the peptide IV-H1 sequence. These studies indicate that peptide IV-H1 represents a cell-specific adhesion, spreading, and motility promoting domain that is active within the type IV collagen molecule.
collagen, since the presence of excess soluble peptide IV-H1 (or polyclonal antibodies generated against peptide IV-H1), inhibited type IV collagen-mediated (but not type I collagen-mediated) melanoma cell adhesion, spreading, and motility. These studies indicate that peptide IV-H1 represents a cell-specific adhesion, spreading, and motility promoting domain that is active within the type IV collagen molecule.

Materials and Methods

Cell Culture

The highly metastatic murine melanoma cell line, termed K1735 M4, was a generous gift from Dr. J. J. Fidler (M. D. Anderson, Houston, TX). This cell line was routinely maintained in DME media (Sigma Chemical Co., St. Louis, MO) supplemented with 10% calf serum (CS). Cells were passaged twice weekly with trypsin as previously described (Chelberg et al., 1989), and care was taken to limit the number of in vitro passages to 8 to minimize phenotypic drift. Dr. Fidler also provided the highly metastatic human melanoma cell line A375 SM, which was maintained in MEM with added vitamins and 10% FBS; and the fibroblastic cell line UV2237 MM, which was maintained in DME with 10% FBS. Other cell lines studied included: the C6 rat glioma cell line (No. CCL107; American Type Culture Collection [ATCC], Rockville, MD), which was maintained in DME plus 10% CS; the SCC9 human squamous carcinoma cell line (No. CRL829; ATCC), which was maintained in a 1:1 solution of DME and HAM F12 containing 10% FBS; the B65 and B104 murine neuroblastoma cell lines that were a generous gift from Dr. David Schubert at the Salk Institute (Schubert et al., 1974) and maintained in F12H media with supplements; and bovine aortic endothelial cells, which were isolated and maintained as described previously (Herbst et al., 1988).

Protein Purification and Preparation of Proteolytic Fragments of Type IV Collagen

Type IV collagen was extracted from the Engelbreth Holm Swarm sarcoma grown in lathyritic mice according to a modification of the method by Kleinman et al. (1982) as previously described (Herbst et al., 1988; Chelberg et al., 1989). Type IV collagen purified by DEAE anion exchange chromatography was subjected to ultracentrifugation at 110,000 g for 90 min to clear aggregates >50S. The supernatant was decanted and stored in 2 M guanidine containing 2 mM DTT at 4°C until needed. The concentration of type IV collagen was determined spectrophotometrically as previously described (Waddell, 1956; Chelberg et al., 1989). Type I collagen (Vitrogen) was obtained from the Collagen Corporation (Palo Alto, CA). Human plasma fibronectin (FN) was purified by sequential ion exchange and gelatin affinity chromatography as described previously (McCarthy et al., 1986).

Peptide Synthesis and Characterization

Peptides representing amino acid sequences from human type IV collagen or FN were synthesized using a peptide synthesizer (990; Beckman Instruments, Inc., Palo Alto, CA), either by Dr. Robert Wohlhueter at the Microchemical Facility of the University of Minnesota, or by Dr. Bianca Conti-Tronconi (University of Minnesota at St. Paul). The procedures used were based on the Merrifield solid phase system as described previously (Stewart and Young, 1984). Lyophilized crude peptides were purified by preparative reverse-phase HPLC on a C-18 column, using an elution gradient of 0-60% acetonitrile with 0.1% trifluoroacetic acid in water. The purity and composition of the peptides was verified by HPLC analysis of acid hydrolysates of the peptides. Peptides, including peptide IV-H1 (GVKGDKGNPGWPG(Y) and a variant of peptide IV-H1 (GVKGDKGNAWAGAAGA, designated peptide IV-H1A), were synthesized from the sequence of the major triple helical domain of human type IV collagen (Table I). As an additional test, an FN-derived peptide 1 (YEKGPGSPVYPRPRGV2, McCarthy et al., 1990) was studied. Certain peptides were synthesized with a tyrosyl residue to the carboxy terminal end to allow radiative iodination of the peptide.

Iodination of Peptides and Determination of Binding Efficiency on Immulon 1 Plates

Labeling of peptides with Na125I was performed as described by McConahey and Dixon (1980). Briefly, 0.1 ng of each peptide in NaHPO4 buffer (pH 7.2) was incubated for 2 min with 0.01 M chloramine T and 0.5 mCi Na125I (New England Nuclear, Boston, MA). The reaction was terminated by the addition of 0.2 ng of Na2S2O5. Free iodine was removed by reverse-phase chromatography using Sep-pak C-18 columns (Waters Division of Millipore, Bedford, MA), from which the radiolabeled peptides were eluted with acetonitrile (50%) containing 0.1% trifluoroacetic acid. The labeled peptides were lyophilized and stored at -80°C until needed. The efficiency of peptide binding to the wells of 96-well polystyrene Immulon 1 plates (Dynatech Laboratories Inc., Chantilly, VA) was determined by drying down 100 μl aliquots of radiiodinated peptides, which had been diluted in Veller's carbonate buffer to concentrations ranging from 1-10 μg/ml. To simulate binding conditions of the peptides in adhesion and spreading assays, the wells were washed and incubated for 2 h with 150 μl/well of a 10 mg/ml solution of BSA in Veller's carbonate buffer. The wells were then washed and the amount of peptides bound to the surfaces was quantitated by solubilizing the peptides with 150 μl/well of 0.5 N NaOH containing 1% SDS. Bound radioactivity was quantitated in a gamma counter (1193; Tm Analytic Inc., Elk Grove Village, IL).

Table I. Type IV Collagen-derived Synthetic Peptides

<table>
<thead>
<tr>
<th>Peptide name</th>
<th>Peptide sequence*</th>
<th>Residue numbers†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peptide 15</td>
<td>GPKEPKVIPFLPG(Y)</td>
<td>634-647</td>
</tr>
<tr>
<td>Peptide 16</td>
<td>GLPGKPSNSDKVDMGSMKK(Y)</td>
<td>930-948</td>
</tr>
<tr>
<td>Peptide 17</td>
<td>GVPKGDQAGPGQP(Q)</td>
<td>975-989</td>
</tr>
<tr>
<td>Peptide 18</td>
<td>GEKDGKGLPDGLD(Y)</td>
<td>1115-1126</td>
</tr>
<tr>
<td>Peptide IV-H1</td>
<td>GVKGDKGPNPGWPG(Y)</td>
<td>1263-1277</td>
</tr>
<tr>
<td>Peptide IV-H1A</td>
<td>GVKGDKGNAWAGAAGA</td>
<td>-</td>
</tr>
</tbody>
</table>

* Using the single-letter amino acid code: A, alanine; D, aspartate; E, glutamate; G, glycine; I, isoleucine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; S, serine; V, valine; W, tryptophan. Each peptide contained a tyrosine residue (Y) at the carboxyl terminal end so that the peptides could be iodinated.

† Residue numbers assigned beginning with amino terminal end, based upon the sequence presented in Muthukumaran et al. (1989).

Generation and Purification of Polyclonal Antibodies

Polyclonal antibodies were generated against peptide IV-H1 coupled to keyhole limpet hemocyanin (KLH; Sigma Chemical Co., St. Louis, MO) using carbodiimide as a coupling agent, based on a procedure described previously (Bauminger and Wilchek, 1980). Briefly, equal amounts (by weight) of peptide and KLH were solubilized in water and mixed with a 10-fold excess (by weight) of 1-ethyl-3-(3-dimethyaminopropyl)-carbodiimide hydrochloride (Sigma Chemical Co.) dissolved in water. New Zealand white rabbits were immunized on the back by multiple subcutaneous injections of ~2 mg/rabbit of peptide/KLH conjugate in complete Freund’s adjuvant. Subsequent biweekly boostos were given intramuscularly in incomplete Freund’s adjuvant. Sera were collected 14 d after the fourth immunization and tested by RIA for reactivity against uncoupled peptide, the protein of origin, and various other ligands. Immune sera were also prepared from rabbits immunized with FN peptide 1 coupled to KLH as a control to confirm the specificity of the antibody response for peptide IV-H1, rather than for the KLH. IgG was purified from normal rabbit sera and pooled immune sera by precipitation with a final concentration of 50% ammonium sulfate overnight at 4°C. The resolubilized precipitate was dialyzed against 0.05 M NaCl in 0.025 M Tris, pH 8.8, and the IgG was purified by DEAE column chromatography as described previously (Skubitz et al., 1987). Purity of the IgG was determined by SDS-PAGE. Retained immunoreactivity of the purified IgG was verified by RIA (Skubitz et al., 1987).

Assays for Antibody Specificity

Immune sera and purified antipeptide IV-H1 IgG were screened for specificity by an indirect solid-phase RIA in 96-well polystyrene Immulon 1 plates as described previously, with minor modifications (Skubitz et al., 1987). Briefly, 50 μl of proteins or peptides at various concentrations in Veller’s carbonate buffer was added to each well and dried overnight at 29°C. The next day, 200 μl of PBS containing 5% BSA (fraction V, fatty acid free, Sigma Chemical Co.), 0.1% Triton X-100, and 0.02% NaN₃ was
added to each well followed by a 60-min incubation at 37°C. After removal of this buffer, 100 μl of purified IgG at various dilutions in PBS containing 5% BSA and 0.02% NaN₃, was added in triplicate and the wells were incubated 1 h at 37°C. After three washings with the above buffer, bound IgG was blocked by the use of a 10 mg/ml solution of BSA in VolleIr's carbonate buffer at 37°C for 2 h. The VolleIr's/BSA solution was then aspirated and 5-6 × 10⁴ cells were added to each well in 150 μl of adhesion media (DME containing 20 mM Hepes and 10 mg/ml BSA). The cells were incubated for 30-40 min at 37°C (or up to 90 min for certain assays), at which time cells were either visualized for spreading or harvested to determine adhesion. Adhesion was quantitated, after washing to remove nonadherent and weakly adherent cells, by solubilizing the cells with 150 μl/well of 0.5 N NaOH containing 1% SDS. Bound radioactivity was quantitated in a liquid scintillation counter (LS 3801; Beckman Instruments). Spreading determinations were made by two different individuals, in double blind studies by visualizing at least 100 cells/well and calculating the percentage of spread cells. Each experiment was repeated a minimum of three times, and within a given experiment, each experimental point was determined in triplicate.

Inhibition of M4 melanoma cell adhesion and spreading on surfaces coated with type IV collagen was monitored in the presence of excess soluble peptides or polyclonal antibodies generated against synthetic peptides. In these assays, Immulon 1 microtiter plates were prepared by drying down 100 μl/well of protein or peptide that had been diluted to various concentrations (1-500 μg/ml) in VolleIr's carbonate buffer. The relative abilities of the peptides to bind the plates was determined using radiiodination of peptides to be certain that any differences in cell adhesion or spreading were not due to differential binding to surfaces. Nonspecific cell adhesion to sites on the plastic was blocked by the use of a 10 mg/ml solution of BSA in VolleIr's carbonate buffer at 37°C for 1 h. After an incubation of 4-5 × 10⁴ cells/ml in DME supplemented with 20 mM Hepes and 10 mg/ml BSA. The cells remained viable (>95%) after this procedure, based upon exclusion of trypan blue dye.

Immulon 1 microtiter plates were prepared by drying down 100 μl/well of protein or peptide that had been diluted to various concentrations (1-500 μg/ml) in VolleIr's carbonate buffer. The relative abilities of the peptides to bind the plates was determined using radiiodination of peptides to be certain that any differences in cell adhesion or spreading were not due to differential binding to surfaces. Nonspecific cell adhesion to sites on the plastic was blocked by the use of a 10 mg/ml solution of BSA in VolleIr's carbonate buffer at 37°C for 1 h. After an incubation of 4-5 × 10⁴ cells/ml in DME supplemented with 20 mM Hepes and 10 mg/ml BSA. The cells remained viable (>95%) after this procedure, based upon exclusion of trypan blue dye.

Inhibition of M4 melanoma cell adhesion and spreading on surfaces coated with type IV collagen was monitored in the presence of excess soluble peptides or polyclonal antibodies generated against synthetic peptides. In these assays, Immulon 1 microtiter plates were prepared by drying down 100 μl/well of protein or peptide that had been diluted to various concentrations (1-500 μg/ml) in VolleIr's carbonate buffer. The relative abilities of the peptides to bind the plates was determined using radiiodination of peptides to be certain that any differences in cell adhesion or spreading were not due to differential binding to surfaces. Nonspecific cell adhesion to sites on the plastic was blocked by the use of a 10 mg/ml solution of BSA in VolleIr's carbonate buffer at 37°C for 1 h. After an incubation of 4-5 × 10⁴ cells/ml in DME supplemented with 20 mM Hepes and 10 mg/ml BSA. The cells remained viable (>95%) after this procedure, based upon exclusion of trypan blue dye.

Cell Adhesion and Spreading Assays

Assays for cell adhesion and spreading were performed as previously described (Chelberg et al., 1989). Briefly, subconfluent cultures of cells were radiolabeled overnight with 2 μCi/ml [³H]thymidine. Before the adhesion assay, cells were released from the culture flasks with 10 mM EDTA in Hank's media or, alternatively, in a trypsin solution (0.05% trypsin with 0.02% EDTA) to confirm that cell adhesion did not require endogenous cell surface proteins that would be retained after EDTA treatment. Cells were then washed and resuspended to a final concentration of 4-5 × 10⁴ cells/ml in DME supplemented with 20 mM Hepes and 10 mg/ml BSA. The cells remained viable (95%) after this procedure, based upon exclusion of trypan blue dye.

Peptide-mediated M4 melanoma cell motility was examined in 48-well microchemotaxis chambers (Neuro Probe, Inc., Cabin John, MD) equipped with 8-μm pore size polystyrene/fibronectin-free polycarbonate filters by a modification of the procedure described previously (Herbst et al., 1988; Chelberg et al., 1989). Briefly, peptides were diluted in VolleIr's carbonate buffer and added in triplicate 50 μl aliquots to the lower wells of the chambers. The chambers were assembled with the filters in place and incubated overnight at 37°C to allow the peptides to adsorb to the lower surfaces of the filters. The filters were then washed, fixed, and stained, and the number of cells that had migrated through the filters was quantitated using an Optomax Image Analysis System, as previously described (Herbst et al., 1988; Chelberg et al., 1989). Each experiment was repeated a minimum of three times.

The ability of peptide IV-H1 or antipeptide IV-H1 polyclonal IgG to inhibit type IV collagen-mediated haptotactic motility was determined by precoating filters on the underside with either type IV collagen or type 1 collagen in VolleIr's carbonate buffer as previously described (McCarthy et al., 1989; Chelberg et al., 1989). The collagen coating concentration (5 μg/ml) was chosen based on the concentration which yielded half-maximal levels of cellular motility (Chelberg et al., 1989). As a control for collagen specificity, certain studies included filters coated with a 5 μg/ml solution of FN, a potent inducer of M4 melanoma cell migration chemotactic activity. The inhibitory effect of peptides on cell motility was determined by...
Table II. Cell Adhesion and Spreading to Substratum-Bound Peptide IV-H1 or Type IV Collagen

<table>
<thead>
<tr>
<th>Cell types</th>
<th>Species of origin</th>
<th>Peptide IV-H1*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Adhesion (%)</td>
</tr>
<tr>
<td>Group 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K1735 M4 melanoma</td>
<td>Mouse</td>
<td>22.4</td>
</tr>
<tr>
<td>A375 M melanoma</td>
<td>Human</td>
<td>16.3</td>
</tr>
<tr>
<td>C6 glioma</td>
<td>Rat</td>
<td>35.9</td>
</tr>
<tr>
<td>B104 neuroblastoma</td>
<td>Rat</td>
<td>18.5</td>
</tr>
<tr>
<td>Group 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bovine aortic</td>
<td>Bovine</td>
<td>0.8</td>
</tr>
<tr>
<td>endothelial cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Squamous cell</td>
<td>Human</td>
<td>1.9</td>
</tr>
<tr>
<td>carcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UV 2237 fibrosarcoma</td>
<td>Murine</td>
<td>1.1</td>
</tr>
<tr>
<td>B65 neuroblastoma</td>
<td>Rat</td>
<td>4.6</td>
</tr>
</tbody>
</table>

* Surfaces were coated with 100 μl/well of peptide IV-H1 or intact type IV collagen at 100 μg/ml in Vogel's carbonate buffer.

Results

Melanoma Cell Adhesion and Spreading on Peptide IV-H1

A number of type IV collagen-derived synthetic peptides were screened for the ability to promote melanoma cell adhesion (Table I). As described previously (Koliakos et al., 1989), 17 peptides were initially selected for synthesis from the published sequence of the major triple helical region of the α1(IV) chain based upon their potential to bind heparin, as a model for glycosaminoglycan binding. The criteria used to select the sequences to be synthesized included the presence of the positively charged amino acid residues arginine and lysine, as well as the presence or absence of discontinuities of the triple helical motif. Although the charges of these peptides were potentially predictive of heparin binding abilities, only a few of the peptides actually did bind heparin (these peptides have been extensively characterized; Koliakos et al., 1989). In the present study, several of those peptides that did not bind heparin were screened for the ability to promote the adhesion of melanoma cells, assuming that the promotion of cell adhesion by these peptides would likely involve a mechanism(s) distinct from binding a cell surface glycosaminoglycan. Only one of the peptides studied (designated IV-H1) promoted significant levels of both adhesion and spreading. This peptide promoted melanoma cell adhesion in a concentration-dependent manner within a coating range of 1-500 μg/ml (Fig. 1 a). Significant cell adhesion (∼35% of input cells) occurred at a coating concentration of 10 μg/ml of peptide IV-H1 and maximal cell adhesion (>50% of input cells) was observed in wells coated with a 100 μg/ml solution of peptide IV-H1. The other peptides studied did not promote significant levels of cell adhesion (<10% over BSA controls), even at the highest concentration of peptide studied (500 μg/ml).

Melanoma cell spreading also occurred on surfaces coated with peptide IV-H1 in a concentration-dependent manner. Maximal spreading (∼70% of input cells) was observed within 40 min at the 200 μg/ml coating concentration of peptide IV-H1 (Fig. 1 b). The other type IV collagen-derived peptides promoted insignificant melanoma cell spreading within the time frame studied.

To ensure that peptide IV-H1-mediated cell adhesion and spreading was not unique to these melanoma cells, various other cell types were screened for adhesion and spreading on surfaces coated with the peptide. Cells of different embryonic origin and from various species were studied for the ability to adhere and spread on surfaces coated with peptide IV-H1. The cell types comprise three major groups (Table II): (Group I) cells that adhered and spread on both peptide IV-H1 and type IV collagen which, in addition to including the high metastatic murine K1735 M4 melanoma, included a highly metastatic human melanoma (A375 M), a rat glioma (C6), and a rat neuroblastoma (B104); (Group 2) cells that

preincubating the cells with increasing concentrations of the peptides for 20 min before the assay to allow for binding to cell surface receptors. Cells in the continued presence of peptides were then added to the upper wells of chambers containing the protein-coated filters. The inhibitory effect of antipeptide IV-H1 IgG on haptotaxis was determined by incubation of the protein-coated filters for 20-30 min with antibody in the lower wells to bind (and thus block) the IV-H1 sequence within the type IV collagen molecule. Cells were then added to the upper wells and the assay proceeded as described above. In addition to IgG purified from normal rabbit sera, IgG generated against peptide 1 coupled to KLH was also used as a negative control to confirm that antibodies generated against KLH did not contribute to the inhibitory effects of the antipeptide IV-H1 IgG.
In the adhesion assays, exogenous soluble peptide IV-HI strongly inhibited IV-HI and type IV collagen-mediated melanoma cell adhesion (Fig. 3 a). Melanoma cell adhesion on surfaces coated with peptide IV-HI was inhibited by nearly 40% in the presence of soluble peptide IV-HI at 20 μg/ml, and by ~80% at the highest concentration of peptide IV-HI tested (500 μg/ml). Similarly, melanoma cell adhesion to surfaces coated with type IV collagen was inhibited by ~20% in the presence of only 20 μg/ml soluble peptide IV-HI, and by as much as 70% at the highest concentration of peptide studied (500 μg/ml). In contrast, melanoma cell adhesion on surfaces coated with type I collagen was not affected by the presence of soluble peptide IV-HI. In addition, no effect of the control peptide 17 (Fig. 3 a) or the FN peptide I (data not shown) on type IV collagen-mediated melanoma cell adhesion was observed, even at the highest concentration tested (500 μg/ml). In all cases using type IV collagen-derived peptides, no inhibition of adhesion was observed on surfaces coated with FN, whereas peptide I specifically inhibited FN-mediated adhesion (data not shown).

Since soluble peptide IV-HI inhibited type IV collagen-mediated melanoma cell adhesion, its effect on cell spreading was next studied. Cell spreading on surfaces coated with peptide IV-HI was inhibited by up to 70% in the presence of soluble peptide IV-HI at 200 μg/ml (Fig. 3 b). Similarly, cell spreading on type IV collagen precoated surfaces was inhibited by 20% at the 100 μg/ml concentration of peptide IV-HI and the level of cell spreading decreased by ~50% at the highest concentration studied (200 μg/ml). In contrast, pretreatment of cells with peptide IV-HI had no effect on the percent of cells spreading on surfaces coated with type I collagen. In control studies, excess peptide 17 (Fig. 3 b) or the FN peptide I (data not shown) had no effect on cell spreading on surfaces coated with type IV collagen or peptide IV-HI. In all cases using type IV collagen-derived peptides, no inhibition of FN-mediated spreading was observed, whereas the FN peptide I specifically inhibited FN-mediated spreading (data not shown).

Finally, type IV collagen-mediated haptotactic melanoma cell motility was studied in the presence of the synthetic peptides. Type IV collagen-mediated cell motility was inhibited by peptide IV-HI in a dose-dependent manner with maximal inhibition of ~80% at the 50 μg/ml level of peptide IV-HI (Fig. 3 c). Melanoma cell motility through filters precoated with type I collagen, however, was not inhibited by the presence of peptide IV-HI. Peptide 17 had no effect on type IV collagen-mediated cell motility. In additional control experiments, the FN peptide I specifically inhibited FN-mediated motility, whereas no inhibition was observed using type IV collagen-derived peptides (data not shown).

Polyclonal IgG Inhibition of Type IV Collagen-mediated Cell Adhesion, Spreading, and Motility

Additional studies were designed to confirm the activity of the IV-HI sequence within intact type IV collagen. In these studies, polyclonal antibodies were generated against pep-

In light of the involvement of cell adhesion and spreading in motility (see Chelberg et al., 1989), peptide IV-HI was studied for its ability to directly promote melanoma cell motility. Peptide IV-HI promoted a concentration-dependent increase in melanoma cell motility in microchambers (Fig. 2). Whereas a significant level of motility (twice BSA control levels) was observed at a coating level as low as 20 μg/ml, maximal cell motility (5× BSA control levels) was observed when the filter was coated with a 100–200 μg/ml solution of peptide IV-HI. This compares with melanoma cell motility of 10-fold background levels in response to a 10 μg/ml solution of intact type IV collagen as previously reported (Chelberg et al., 1989).

Inhibition of Cellular Adhesion, Spreading, and Motility by Exogenous Peptide IV-HI
Since peptide IV-HI was observed to promote cell adhesion, spreading, and motility, it was necessary to demonstrate the activity of the IV-HI sequence within the intact type IV collagen molecule. Thus, studies were performed to determine the ability of the peptide to inhibit type IV collagen-mediated M4 melanoma cell adhesion, spreading, and migration. The specificity of the peptide IV-HI sequence within type IV collagen was determined by including type I collagen and FN in the inhibition studies. As additional controls, two other peptides, type IV collagen peptide 17 and FN peptide I, were studied for the ability to inhibit collagen-mediated cell activity. Cells remained viable in the presence of all concentrations of peptides studied, as demonstrated by exclusion of trypan blue dye (data not shown).
Table III. Reactivity of Antibody Raised against Peptide IV-H1

<table>
<thead>
<tr>
<th>Protein or peptide (ligand)</th>
<th>IgG Concentration (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.001*</td>
</tr>
<tr>
<td>Peptide IV-H1</td>
<td>2,996†</td>
</tr>
<tr>
<td>Type IV collagen</td>
<td>127</td>
</tr>
<tr>
<td>Type I collagen</td>
<td>69</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>88</td>
</tr>
</tbody>
</table>

* Purified antipeptide IV-H1 IgG was screened for specificity by an indirect solid-phase RIA. Briefly, surfaces were coated with proteins or peptides as described in Materials and Methods. Purified IgG at various dilutions were added. Bound IgG was detected by the addition of [125I]-labeled secondary IgG (sp act, 5 μCi/µg).

† Quantitation of [125I]-labeled secondary IgG bound, expressed as counts per minute.

Figure 3. Inhibition of adhesion, spreading, and motility on type IV collagen by peptide IV-H1. 3H-Thymidine-labeled M4 melanoma cells were preincubated with increasing concentrations of soluble peptides and cell adhesion or spreading on peptide- or protein-coated surfaces was determined in the continued presence of the peptides. Cell adhesion (a) or spreading (b) in the presence of soluble peptide IV-H1 was determined on surfaces coated with 5 µg/ml type IV collagen (■) or type I collagen (○), or 50 µg/ml peptide IV-H1 (●); or in the presence of peptide 17 on surfaces coated with 5 µg/ml type IV collagen (■). Data are presented as the percent of cells adherent or spread in the presence of peptide relative to adhesion/spreading in the absence of soluble peptide. (c) Filters were coated on the underside with either type IV collagen or type I collagen as described in Materials and Methods. Cell migration was quantitated in the presence of soluble peptide IV-H1 and tested for the ability to inhibit type IV collagen-mediated M4 melanoma cell adhesion, spreading, and motility. Purified IgG generated against KLH-coupled peptide IV-H1 was screened for immunoreactivity by RIA (Table III). Reactivity of antipeptide IV-H1 IgG was type IV collagen-specific, since the IgG recognized type IV collagen and peptide IV-H1 but not type I collagen or FN. The controls, purified normal rabbit IgG or purified IgG generated against the FN peptide I coupled to KLH did not react with type IV collagen or any of the synthetic type IV collagen-derived peptides, although antipeptide I IgG specifically reacted with FN (data not shown).

Melanoma cell adhesion on surfaces coated with peptide IV-H1, intact type IV collagen, or type I collagen was monitored in the presence of increasing concentrations of antipeptide IV-H1 IgG. Melanoma cell adhesion on surfaces coated with 50 µg/ml of peptide IV-H1 was inhibited ~40% by anti-IV-H1 IgG at 20 µg/ml (Fig. 4a). Maximal inhibition (70%) was observed at the highest concentration of antibody tested (500 µg/ml). Cell adhesion to type IV collagen was also reduced in a concentration-dependent manner by preincubation with anti-IV-H1 IgG. Significant inhibition (20%) was observed in the presence of only 20 µg/ml of antipeptide IV-H1 IgG, and a 40% inhibition of adhesion was observed at 500 µg/ml of antipeptide IV-H1 IgG. In contrast, preincubation with the antipeptide IV-H1 IgG did not reduce the levels of melanoma cell adhesion to surfaces coated with type I collagen. No inhibition of cell adhesion to surfaces coated with any of the collagenous proteins was observed in the presence of normal rabbit IgG or anti-FN peptide I IgG, even at the highest concentration used (500 µg/ml); demonstrated by the lack of inhibition of cell adhesion to peptide IV-H1 with normal rabbit IgG (Fig. 4a). As expected, antipeptide I IgG reduced cell adhesion to FN by up to 60% (data not shown).

Melanoma cell spreading on surfaces coated with peptide IV-H1, intact type IV collagen, or type I collagen was moni-
Figure 4. Anti-IV-H1 IgG inhibition of melanoma cell adhesion, spreading, and motility on type IV collagen. (a) Immulon I plates were coated, as described in Materials and Methods, with peptide IV-H1, type IV collagen, or type I collagen (50 μg/ml, 5 μg/ml, and 5 μg/ml, respectively). Coated surfaces were preincubated with increasing concentrations of anti-IV-H1 IgG or normal rabbit IgG, then cells were added in the continued presence of IgG. Data are presented as the percent of cells adherent in the presence of antipeptide IV-H1 IgG on surfaces coated with type IV collagen (I), type I collagen (o), or peptide IV-H1 (o), or in the presence of normal rabbit IgG on type IV collagen (zx). (b) Assay proceeded as in a. Data are presented as the percent of cells spreading in the presence of antipeptide IV-H1 IgG on surfaces coated with type IV collagen (I), type I collagen (o), or peptide IV-H1 (o), or in the presence of normal rabbit IgG on type IV collagen (zx). Data are expressed as the percent of cell adhesion/spreading in the presence of IgG, relative to adhesion/spreading in the absence of IgG (represented as the 0 concentration). (c) Polycarbonate filters were coated on the underside with either type IV collagen or type I collagen, as described in Materials and Methods. Antipeptide IV-H1 or normal rabbit IgG was added to the lower wells of the motility assay before the addition of cells to the motility assay (Fig. 4 c). Motility was decreased in a concentration-dependent manner with maximal inhibition of 70% at 100 μg/ml of IgG. In contrast, cell motility through filters precoated with type I collagen (Fig. 4 c) or FN (data not shown) was not inhibited by preincubation of the filters with antipeptide IV-H1 IgG. Normal rabbit IgG had no effect on type IV collagen-mediated cell motility.

Melanoma Cell Adhesion, Spreading, and Motility on Alanyl-substituted Peptide IV-H1

In light of the reported importance of prolyl residues in mediating cell adhesion on collagen-coated surfaces (Rubin et al., 1981), a substituted version of peptide IV-H1 was synthesized to determine the relative importance of these residues in the ability of peptide IV-H1 to promote M4 melanoma cell adhesion, spreading, and motility. This peptide, designated IV-H1A, contained alanyl residues (A) in place of the three prolyl residues of the IV-H1 sequence (GVKG-DKGNAGWAGAA). Melanoma cell adhesion was essentially unaffected by the alanyl-substitution of peptide IV-H1, since cells adhered to nearly the same extent on surfaces coated with either peptide IV-H1 or IV-H1A (Fig. 5). However, cells exhibited a substantially decreased ability to spread on surfaces coated with peptide IV-H1A compared to spreading on peptide IV-H1 (Fig. 6). This occurred at all concentrations of the peptides (5-500 μg/ml) and at all time points monitored (20-90 min). Studies in which these two peptides were radiolabeled and bound to the plates indicated that pep-
tide IV-H1A binds to the plates as well as or better than native peptide IV-H1 at all concentrations tested (Table IV). These findings indicate that the reduced spreading of cells that was observed on surfaces coated with peptide IV-H1A was not due simply to failure of this peptide to bind to the plates.

In addition to decreasing the ability of peptide IV-H1 to promote melanoma cell spreading, the alanyl substitutions also decreased the ability of peptide IV-H1 to promote melanoma cell motility. Cell motility was not observed through filters coated with peptide IV-H1A, even at the highest concentrations tested (Fig. 7), whereas peptide IV-H1-coated filters promoted significant cell motility at levels as low as 10 μg/ml. The relative abilities of the peptides to bind to the filters was determined using radioiodinated peptides to be certain that the differences in motility were not due to differential binding of the peptides to the filters. The studies demonstrated that peptide IV-H1A and peptide IV-H1 bound to the filters to similar extents (Table IV).

Discussion

A growing body of evidence, including the identification of type IV collagen–specific integrin-like receptors on the surface of tumor cells (Tomaselli et al., 1988; Kramer and Marks, 1989) indicates that BM type IV collagen may play a major role in tumor cell invasion of BM. Cell adhesion and motility on BM components have been described as necessary steps in BM invasion (Liotta, 1977). Our earlier studies (Chelberg et al., 1989) presented data that indicated that both the purified helical p-IV fragment and the NC1 domain of type IV collagen supported in vitro M4 melanoma cell adhesion and spreading. Only the p-IV fragment promoted cell motility. In addition, our findings indicated that these cell activities (adhesion and spreading) are necessary, albeit insufficient, for successful cell motility. Since cell motility is instrumental in tumor cell invasion of BM, the triple helical portion of type IV collagen has become a major focus of our further investigation. The current studies
have been designed to further understand the molecular basis of the cellular responses promoted by the p-IV fragments. To this end, several synthetic peptides, derived from the $a_1$ chain of the major triple helical region of human type IV collagen, have been screened for the ability to promote cell adhesion and spreading.

The present studies indicate that a type IV collagen-derived sequence, designated peptide IV-H1, represents a cell adhesion, spreading, and motility promoting domain within the type IV collagen molecule. This is supported in part by the observations that peptide IV-H1 promoted these cellular activities in a concentration-dependent manner in studies using the highly metastatic M4 melanoma cell line. In addition, peptide IV-H1, or a polyclonal antibody directed against peptide IV-H1, inhibited type IV collagen-mediated melanoma cell adhesion, spreading, and motility. The latter results indicate that the sequence represented by peptide IV-H1 is active within the intact type IV collagen molecule.

Current studies have demonstrated receptors that recognize both type IV and either native type I collagen or gelatin (Kurkinen et al., 1984; Sugrue, 1987; Kramer and Marks, 1989). However, the findings presented here indicate that the effects of the peptide IV-H1 sequence are specific to type IV collagen. This is supported, in part, by our observations that type I collagen-mediated melanoma cell adhesion, spreading, and motility were not affected in competition studies by peptide IV-H1 or antipeptide IV-H1 IgG, and is consistent with the observed absence of a IV-H1-like sequence within type I collagen in computer searches (using the ALLIGN option of the PEP software or the QUEST program of the Intelligenetics Software package). It will be necessary, in future studies, to isolate a cell surface receptor that recognizes the sequence of peptide IV-H1 to test this hypothesis directly.

Studies of the adhesion and spreading of various normal and tumor cell types to surfaces coated with type IV collagen or peptide IV-H1 support a cell type-specific interaction with the IV-H1 sequence. In addition to the murine K1735 M4 melanoma cell line, cell lines derived from a human melanoma, a rat glioma, and a rat neuroblastoma were all observed to adhere and spread extremely well on surfaces coated with the human-derived peptide IV-H1. These findings support the possibility that the activity of the IV-H1 sequence in type IV collagen is conserved across species. This may be expected since the amino acid sequence of the entire type IV collagen molecule is highly conserved between the human and murine species (Muthukumar et al., 1989). It will be of interest to further define the minimal sequence within peptide IV-H1 that supports cellular adhesion and motility, and to determine the sequence homology across species of this determinant.

Cell type specificity of peptide IV-H1-mediated cell adhesion and spreading was demonstrated by other cell types that strongly adhere to surfaces coated with type IV collagen, but which exhibited no adhesion to surfaces coated with peptide IV-H1. These cell types are represented in the current studies by the human squamous carcinoma cell line and bovine aortic endothelial cells. These observations suggest that different mechanisms for cell adhesion and spreading on type IV collagen may be used by different cell types. Additional cells, including a fibrosarcoma and neuroblastoma cell line, did not adhere to either intact type IV collagen or peptide IV-H1. It is worth noting that no cells were found to adhere to peptide IV-H1 which also did not adhere to intact type IV collagen. Taken with the results of the inhibition studies, this observation supports our assumption that the activity of peptide IV-H1 was not created upon removal of the sequence from the context of the intact type IV collagen molecule.

A peptide was synthesized, designated IV-H1A, in which alanine residues were substituted for the three prolyl residues within the IV-H1 sequence, to confirm that the prolyl residues alone were not responsible for the activity of peptide IV-H1. Previous studies by Rubin et al. (1981) indicated that multiple prolyl residues presented in the collagenous helical motif promoted hepatocyte adhesion. In their studies, the tripeptide gly-X-pro repeat sequence promoted significant levels of adhesion, although reduced relative to intact collagens of various types or the cyanogen bromide-derived fragments of type I collagen. The conservative substitutions of alanine residues for prolyl residues in the present studies drastically decreased the spreading and motility promoting activities of peptide IV-H1A relative to the parent IV-H1. These observations suggest that the prolyl residues are crucial for maintenance of the full repertoire of functions of the active sites within peptide IV-H1, in agreement with the findings of Rubin et al. (1981). Melanoma cell adhesion, however, was not affected by the amino acid substitutions. Taken together, these observations indicate that conservation of the prolyl residues is crucial for the full complement of IV-H1 sequence activities, but that other factors within peptide IV-H1 are also involved in promoting cell attachment. Although we do not presently have an explanation for these observations, the collagenous helix would be predicted to be more closed (<3.2 $\AA$/turn) in the absence of the prolyl residues, which would alter the conformation of an active site. Additional studies are currently being performed to further establish the active site within peptide IV-H1. These studies, in combination with the isolation of a receptor(s) recognizing this sequence, will shed new light on the molecular basis of type IV collagen-mediated cell adhesion, spreading, and motility.

Figure 7. Directional motility of melanoma cells in response to the alanyl-substituted peptide IV-H1. Polycarbonate filters were coated as described in Materials and Methods with peptide IV-H1 (o) or peptide IV-H1A (●). Cell motility in response to these peptides was quantitated by image analysis microscopy. All data represent the means of at least three experiments in which triplicate determinations were made ± SEM.
The helpful comments and suggestions of Dr. John Alegrè, Dr. Rod切尔柏格, and Dan Mickelson are gratefully acknowledged. We also thank Suzanne Warmka, Judy Kahm, and Eric Kjellesvig for excellent technical assistance.

This research has been supported, in part, by funds from National Cancer Institute/National Institutes of Health (NIH) grants CA 43924 and grants from the Elsa Pardee Foundation and the Leukemia Task Force to J. B. McCarthy, as well as a grant from the Juvenile Diabetes Association to A. P. N. Skubitz, NIH grants CA 29995, CA 21463 and EY 06625 to L. T. Furcht, and funds from NIH/National Institutes of Diabetes and Digestive and Kidney Disorders CA 39216 to E. C. Tsilibary. L. T. Furcht is a recipient of the Pardee Professorship of Cancer Biology. This manuscript is part of a doctoral thesis by M. K. Chelberg in partial fulfillment of the requirements of the graduate school of the University of Minnesota.

Received for publication 12 December 1989 and in revised form 26 February 1990.

References


